Cardiovascular and kidney outcomes In patients with diabetes, GLP-1s are now FDA-approved to reduce major adverse cardiac events (MACE) and slow chronic kidney disease progression
But how do they work, and why are they garnering so much attention
however, the understanding of GIP's biology was overshadowed by research focusing on GLP-1 and its impact in diabetes and obesity treatment [4, 11,12,13,14]
When youre taking a GLP-1 medication, your appetite is dramatically suppressed
What I recommend as a Transcend Company first time peptide protocol
Patients taking other glucose-lowering agents may experience more rapid glycemic improvements, though this must be balanced against increased hypoglycemia risk when combined with insulin or sulfonylureas